A Phase 1, Randomized, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine at Two Dose Levels of the ID93 Antigen and the GLA-SE Adjuvant in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2018
At a glance
- Drugs ID 93/GLA-SE (Primary) ; ID 93
- Indications Tuberculosis
- Focus Adverse reactions
- 19 Feb 2018 According to an Aeras media release, follow up data from this study will be presented at 5th Global Forum on Tuberculosis 2018.
- 13 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.